BNT111 (BioNTech) — an investigational cancer immunotherapy — uses a fixed combination of mRNA-encoded, tumor-associated antigens designed to activate a precise and strong immune response against cancer.
Regulatory
FDA Approves Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma Following CR
The FDA has approved pembrolizumab (Keytruda) for the adjuvant treatment of adult and pediatric patients with stage IIB or IIC melanoma following complete resection (CR).
FDA approves adjuvant Keytruda for certain adults, children with stage IIB, IIC melanoma
The FDA approved pembrolizumab as adjuvant therapy for adults and children aged 12 years or older with stage IIB or IIC melanoma after complete resection.
FDA Orphan Drug Designation Granted to ST101 for Advanced Cutaneous Melanomas
The FDA granted a fast track designation to ST101 for the treatment of advanced cutaneous melanoma in patients who have disease progression on or after anti-PD-1/anti-PD-L1 therapy.